Matsumoto, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 (Shiba-Kyoritsu)

Position

Professor
Page Top ▲

Career 【 Display / hide 】

  • 2003.04
    -
    2007.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 医療職員

  • 2007.04
    -
    2014.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 主任

  • 2014.04
    -
    2017.03

    慶應義塾大学薬学部, 実務薬学講座, 准教授

  • 2017.04
    -
    Present

    慶應義塾大学薬学部, 薬効解析学講座, 教授

Page Top ▲

Academic Background 【 Display / hide 】

  • 1994.04
    -
    1998.03

    Kumamoto University, 薬学部, 薬学科

    University, Graduated

  • 1998.04
    -
    2000.03

    Kumamoto University, 薬学研究科

    Graduate School, Completed, Master's course

  • 2000.04
    -
    2003.03

    Kumamoto University, 薬学研究科

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（薬学）, Kumamoto University, Coursework, 2003.03

    α1-酸性糖蛋白質の生理作用と動態特性に関する研究

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 薬剤師免許証, 1998.07

  • 日本薬剤師研修センター認定薬剤師, 2006.03

  • 日本医療薬学会認定薬剤師, 2009.01

  • インフェクションコントロールドクター, 2009.01

  • 感染制御専門薬剤師, 2009.03

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Clinical pharmacy

Page Top ▲

Research Keywords 【 Display / hide 】

  • Drug Delivery System

  • 抗菌化学療法

  • 高齢者医療

Page Top ▲

Research Themes 【 Display / hide 】

  • 医薬品の薬効評価と副作用解析に基づいた薬物療法の最適化に関する研究, 

    2014.04
    -
    Present

Page Top ▲
 

Books 【 Display / hide 】

  • ケースで学ぶ老年薬学

    松元一明, 日経BP, 2024.01

    Scope: 感染症.

  • 今日の治療指針2024

    松元一明, 医学書院, 2024.01

    Scope: 市中肺炎/急性中耳炎 服薬指導・薬剤情報

  • 今日の治療薬2024

    松元一明, 南江堂, 2024.01

  • マナビジュアルノート 感染症・病原体とくすり

    松元一明, 南山堂, 2023.12

  • 薬がみえる vol 3 第2版

    松元一明, メディックメディア, 2023.09

    Scope: 抗菌薬/細胞壁合成阻害薬.

display all >>

Page Top ▲

Papers 【 Display / hide 】

  • Bacteremia and meningitis caused by penicillin-resistant <i>Streptococcus pneumoniae</i> serotype 35B successfully treated with ceftriaxone combined with vancomycin followed by linezolid: A case report

    Tomioka Mifumi, Nakamura Kiwamu, Duan Shaoqing, Matsumoto Kazuaki, Shindo Takahiro, Hoshi Keisuke, Nagao Mika, Oshima Fuminari, Hara Yasuka, Namai Yoshiyuki

    Internal Medicine (The Japanese Society of Internal Medicine)  advpub ( 0 )  2024.11

    Joint Work,  ISSN  0918-2918

    　View Summary

    <p>We herein report a case of bacterial meningitis and bacteremia in a 3-month-old boy caused by <i>Streptococcus pneumoniae</i> serotype 35B multidrug resistance. Intravenous ampicillin was administered on admission. However, when pneumococcal meningitis was suspected, the antibiotic treatment was changed to ceftriaxone (CTRX) and vancomycin (VCM). However, owing to difficulties in achieving sufficient serum trough levels of VCM, this treatment was again switched to linezolid (LZD). The patient recovered without complications after 16 days of CTRX and LZD treatment. This case suggests that LZD is a viable treatment option for bacterial meningitis. </p>

  • Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis.

    Liu X, Enoki Y, Taguchi K, Matsumoto K

    The Journal of pharmacy and pharmacology  2024.11

    Joint Work,  ISSN  0022-3573

  • Investigating the hypothermic effects of fluoroquinolone antimicrobials on non-bacterial fever model mice.

    Hara R, Taguchi K, Ogino H, Okamoto Y, Enoki Y, Kizu J, Hori S, Matsumoto K

    Journal of pharmaceutical health care and sciences 10 ( 1 ) 68 2024.11

    Joint Work,  ISSN  2055-0294

    　View Summary

    Background: Fluoroquinolone (FQ) antimicrobials have antipyretic effects during the treatment of bacterial infections; however, it is not clear whether these are due to their antimicrobial activities or their hypothermic effects. In this study, we investigated the hypothermic effects of FQ antimicrobials (ciprofloxacin [CPFX], gatifloxacin [GFLX], and levofloxacin [LVFX]) on fever by evaluating rectal body temperature changes in a mouse model of non-bacterial fever. Methods: CPFX, GFLX, and LVFX were administered intraperitoneally to non-bacterial fever model mice induced by yeast. Rectal body temperature was measured up to 180 min after administration. Results: A decrease in rectal body temperature of up to 1.2 °C for CPFX, 3.4 °C for GFLX, and 1.0 °C for LVFX was observed. The decrease in temperature was induced by an increase in the plasma concentration of FQ antimicrobials, suggesting that they are responsible for the temperature reduction. Focusing on glucocorticoids, one thermoregulation mechanism, we investigated the substances responsible for the reduction in rectal body temperature induced by FQ antimicrobials. Aminoglutethimide (an inhibitor of glucocorticoid production) were premedicated, followed by intraperitoneal administration of GFLX in the yeast-induced fever mouse model, resulting in attenuated GFLX-induced hypothermic effects. Conclusions: These results suggest that certain antipyretic effects of CPFX, GFPX, and LVFX during fever may contribute to their hypothermic effects; certain mechanisms are glucocorticoid-mediated.

  • Optimal Teicoplanin Trough Concentration With Therapeutic Drug Monitoring in Children: A Systematic Review and Meta-analysis.

    Hanai Y, Oda K, Ueda T, Matsumoto K, Murakami L, Uekusa S, Ohashi H, Nishimura K, Takesue Y, Matsuo K

    Therapeutic drug monitoring  2024.07

    Joint Work,  ISSN  0163-4356

    　View Summary

    Background: Teicoplanin is used to treat serious Gram-positive bacterial infections. However, the optimal trough concentrations for pediatric patients remain unclear owing to the lack of monitoring guidelines. This study aimed to determine the optimal teicoplanin trough concentration for treating Gram-positive bacterial infections in children. Methods: A systematic review was conducted using 4 databases. Stepwise cutoffs within the range of 10–30 mcg/mL were used for efficacy and safety. Studies were included if they reported treatment success rates and/or all-cause mortality, nephrotoxicity, hepatotoxicity, and thrombocytopenia according to the trough concentration. Results: The meta-analysis included 12 studies involving 830 pediatric patients. Teicoplanin cutoff values of 10, 15, 20, and 30 mcg/mL were reported in 9, 8, 9, and 2 studies, respectively. Trough concentrations,10 mcg/mL significantly reduced the treatment success rate, with an odds ratio of 0.07 and a 95% confidence interval ranging from 0.01 to 0.40. The overall treatment success rate was 50.0% versus 95.7% observed at concentrations $10 mcg/mL. However, no significant difference was observed at the 15-, 20-, and 30-mcg/mL cutoffs, when compared with lower concentrations. Trough concentrations,20 mcg/mL were associated with a decreased risk of nephrotoxicity (odds ratio = 0.21; 95% confidence interval, 0.08–0.55). However, hepatotoxicity and thrombocytopenia showed no significant associations with trough concentration ranges between 10 and 30 mcg/mL. Conclusions: Although further prospective studies are required for validation, the authors’ findings suggest that 10- to 20-mcg/mL teicoplanin is the optimal trough concentration for enhanced clinical success and reduced toxicity in pediatric patients.

  • Anti-edematous effects of epinastine, cetirizine and its enantiomers in λ-carrageenan-induced edema in rat hind paw

    Taguchi K., Chuang V.T.G., Ozawa M., Sakamoto Y., Hara R., Iketani O., Enoki Y., Kizu J., Hori S., Matsumoto K.

    Pharmazie (Pharmazie)  79 ( 6 ) 98 - 100 2024.06

    Joint Work,  ISSN  00317144

    　View Summary

    Urticaria is induced by the histamine released from mast cells which develops wheals (edema) as a visual feature. In clinical practice, second-generation histamine H1-receptor blockers are routinely used as the first-line symptomatic treatment for urticaria. Nevertheless, not much research has directly examined the second-generation histamine H1-receptor blockers’ ability to reduce edema. In this study, we directly evaluated the anti-edematous activities of three second-generation histamine H1-receptor blockers available in the market (epinastine hydrochloride, cetirizine hydrochloride, and levocetirizine hydrochloride) using a λ-carrageenan-induced footpad edema model. One hour before the induction of edema with 1% λ-carrageenan injection, all second-generation histamine H1-receptor blockers (5, 10, 50 and 100 mg/kg) were subcutaneously administered to rats. At 0.5 and 3 hours after λ-carrageenan administration, the edema volume was evaluated using a Plethysmometer. Epinastine hydrochloride significantly suppressed the edema growth in a dose-dependent manner. Cetirizine hydrochloride showed a slight anti-edematous effect, while levocetirizine significantly inhibited the development of edema in a dose-dependent manner. On the other hand, dextrocetirizine did not prevent edema from growing. In summary, second-generation histamine H1-receptor blockers, at least those examined in this study, may be able to reduce the clinical symptoms of urticaria associated with edema. Levocetirizine hydrochloride is also anticipated to have stronger anti-edematous effects than cetirizine hydrochloride because levocetirizine is responsible for cetirizine’s anti-edematous activity.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • MRSA感染症の診療ガイドライン2024

    光武 耕太郎, 松本 哲哉, 植田 貴史, 内山 勝文, 小澤 俊幸, 唐牛 春香, 菅井 基行, 関 雅文, 高橋 聡, 竹末 芳生, 中嶋 一彦, 中嶋 秀人, 中南 秀将, 畑 啓昭, 藤倉 雄二, 藤村 茂, 松下 和彦, 松元 一明, 三鴨 廣繁, 宮入 烈, 柳原 克紀, 山岸 由佳, 山口 哲央, 山田 浩司, 山本 善裕, 吉田 耕一郎, 池田 信介, 岩田 栄一朗, 大野 久美子, 大野 智裕, 加勢田 富士子, 加藤 秀雄, 加茂野 絵美, 川崎 洋平, 川筋 仁史, 小林 直実, 坂 なつみ, 瀬戸 良教, 高野 昇太郎, 浜田 幸宏, 松本 浩, 荒川 創一, 岩田 敏, 金光 敬二, 公益社団法人日本化学療法学会, 一般社団法人日本感染症学会MRSA感染症の診療ガイドライン作成委員会

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 3 ) 251 - 321 2024.05

    ISSN  1340-7007

  • ICU症例におけるバンコマイシンの目標AUC達成因子解析

    石郷 友之, 藤居 賢, 伊部 裕太, 相神 智宏, 吉田 博昭, 田中 宏明, 海老原 文哉, 丸山 拓実, 鈴木 絢子, 佐村 優, 南雲 史雄, 小松 敏彰, 冨澤 淳, 詫間 章俊, 千葉 博暁, 榎木 裕紀, 田口 和明, 浜田 幸宏, 西 圭史, 松元 一明, 福土 将秀

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 109 - 110 2024.01

    ISSN  1340-7007

  • Mycobacterium abscessus complexに対するNacubactamとβラクタム系薬2剤併用の有効性評価

    三澤 可奈, 西村 知泰, 吉川 万衣子, 島村 莉奈, 榎木 裕紀, 田口 和明, 松元 一明, 長谷川 直樹

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 97 - 97 2024.01

    ISSN  1340-7007

  • 同種造血幹細胞移植後にポサコナゾール腸溶錠の血中濃度が低値を示した一例

    島村 千陽, 坂本 靖宜, 長谷川 拓也, 榎木 裕紀, 田口 和明, 松元 一明

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 116 - 116 2024.01

    ISSN  1340-7007

  • バンコマイシン投与で2点採血を実施した患者における1点採血と2点採血の比較

    鈴木 絢子, 佐村 優, 石郷 友之, 伊部 裕太, 相神 智宏, 吉田 博昭, 田中 宏明, 海老原 文哉, 丸山 拓実, 南雲 史雄, 小松 敏彰, 冨澤 淳, 千葉 博暁, 詫間 章俊, 榎木 裕紀, 田口 和明, 浜田 幸宏, 西 圭史, 藤居 賢, 松元 一明, 山口 史博, 藤原 久登

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 109 - 109 2024.01

    ISSN  1340-7007

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築.

    並木孝哉、横山雄太、枦秀樹、織田錬太郎、地引綾、河添仁、松元一明、鈴木小夜、中村智徳.

    第44回日本臨床薬理学会学術総会 (兵庫県) , 

    2023.12
    , 

    Oral presentation (general)

  • 第2部：抗微生物薬の選択と投与「TDMガイドラインのupdate」

    松元一明.

    敗血症WEBセミナー2023 微生物との対峙 (東京都) , 

    2023.12
    , 

    Public lecture, seminar, tutorial, course, or other speech

  • 抗菌薬投与によるMycobacterium abscessusのコロニー形態変化.

    島村莉奈、西村知泰、三澤可奈、吉川万衣子、柏村祥子、矢野大和、矢野郁也、榎木裕紀、田口和明、松元一明、長谷川直樹.

    第54回結核・非定型抗酸菌症治療研究会 (東京都) , 

    2023.12
    , 

    Oral presentation (general)

  • Mycobacterium abscessus complexに対してナキュバクタムとβラクタム系薬2剤併用は有効である.

    三澤可奈、西村知泰、吉川万衣子、島村莉奈、柏村祥子、榎木裕紀、田口和明、松元一明、長谷川直樹.

    第54回結核・非定型抗酸菌症治療研究会 (東京都) , 

    2023.12
    , 

    Oral presentation (general)

  • 薬剤感受性試験によるMycobacterium avium complexに対するβ-ラクタム系抗菌薬2剤併用の有効性評価.

    吉川万衣子、西村知泰、三澤可奈、島村莉奈、柏村祥子、榎木裕紀、田口和明、松元一明、長谷川直樹.

    第54回結核・非定型抗酸菌症治療研究会 (東京都) , 

    2023.12
    , 

    Oral presentation (general)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 新規肺MABC症治療薬の開発と革新的非臨床PK/PD評価法の構築

    2024.04
    -
    2028.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • 薬剤耐性淋菌・緑膿菌に有効な新規抗菌剤の開発

    2023.08
    -
    2024.03

    国立研究開発法人日本医療研究開発機構（AMED）, 新興・再興感染症に対する革新的医薬品等開発推進研究事業, Joint research, Coinvestigator(s)

  • ホローファイバー感染モデルを用いたカルバペネム耐性菌感染症の抗菌薬併用療法に関する橋渡し研究

    2022.04
    -
    2025.03

    国立研究開発法人国立国際医療研究センター, 国際医療研究開発事業, Joint research, Coinvestigator(s)

  • マウス肺感染モデルを用いたOP0595の臨床有効性予測

    2022.01
    -
    2024.03

    Meiji Seikaファルマ株式会社, Commissioned ｒesearch, Principal investigator

  • Investigation of the effectiveness of imeglimin as a potential therapeutic agent for sarcopenia

    2021.09
    -
    2023.08

    大日本住友製薬株式会社, Commissioned ｒesearch, Principal investigator

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Date applied： 特願2020-144044  2020.08 

    Patent, Joint

Page Top ▲

Awards 【 Display / hide 】

  • 第44回日本臨床薬理学会学術総会優秀発表賞

    並木孝哉、横山雄太、枦秀樹、織田錬太郎、地引綾、河添仁、松元一明、鈴木小夜、中村智徳., 2023.12, 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築.

  • 第17回日本腎臓病薬物療法学会学術集会・総会2023優秀演題賞

    石郷友之、藤居賢、伊部裕太、吉田博昭、田中宏明、海老原文哉、丸山拓実、鈴木絢子、佐村優、南雲史雄、小松敏彰、冨澤淳、詫間章俊、千葉博暁、榎木裕紀、田口和明、浜田幸宏、西圭史、松元一明、福土将秀., 2023.10,  ICU症例におけるバンコマイシンの急性腎障害と早期AUCとの関連性.

  • 日本薬学会第143年会 学生優秀発表賞 口頭発表の部

    長邑花, 榎木裕紀, 田口和明, 松元一明., 2023.04, 骨格筋萎縮による敗血症病態の増悪と免疫状態変動の関与.

  • 第14回日本化学療法学会東日本支部 支部長賞（基礎）

    田代渉、榎木裕紀、田口和明、松元一明, 2023.01, Clostridioides difficileに対するfidaxomicinのin vitro抗菌活性評価及びin vivo感染マウスモデルを用いた糞中PK/PD評価

  • 第29回日本血液代替物学会年次大会学生講演賞

    伊藤千尋、田口和明、山田大雅、榎木裕紀、小松晃之、松元一明, 2022.12, ドキソルビシン担持一酸化炭素結合型ヘモグロビン-アルブミンクラスターの創製と抗腫瘍効果の評価

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • RESEARCH FOR BACHELOR'S THESIS 1

    2024

  • PROJECT FOR MULTIDISCIPLINARY AND INTERDISCIPLINARY KNOWLEDGE (SUSTAINABLE ENVIRONMENT)

    2024

  • PRIOR LEARNING FOR CLINICAL PRACTICE 4

    2024

  • PRIOR LEARNING FOR CLINICAL PRACTICE 3

    2024

  • PRIOR LEARNING FOR CLINICAL PRACTICE 1

    2024

display all >>

Page Top ▲
 

Social Activities 【 Display / hide 】

Page Top ▲

Memberships in Academic Societies 【 Display / hide 】

  • 日本医真菌学会, 

    2019.02
    -
    Present

  • 日本DDS学会, 

    2018.05
    -
    Present

  • 日本臨床微生物学会, 

    2018.03
    -
    Present

  • 日本老年薬学会　理事・評議員, 

    2016.04
    -
    Present

  • 日本薬剤学会　代議員, 

    2015.12
    -
    Present

display all >>

Page Top ▲